X
<

Bristol-Myers Squibb’s Latest Developments and Valuation

PART:
1 2 3 4 5 6 7 8
Part 8
Bristol-Myers Squibb’s Latest Developments and Valuation PART 8 OF 8

Must-Know Changes to Bristol-Myers Squibb’s Valuation

Bristol-Myers Squibb’s valuation

Bristol-Myers Squibb (BMY), a US pharmaceutical company, includes innovative products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises. The company’s headquarters are in New York City.

Must-Know Changes to Bristol-Myers Squibb’s Valuation

Interested in BMY? Don't miss the next report.

Receive e-mail alerts for new research on BMY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart shows revenues and earnings per share (or EPS) for BMY over the last few quarters and estimates for 3Q17. Wall Street analysts estimate EPS of $0.76 on revenues of $5,167 million for 3Q17. 

Forward PE

PE or price-to-earnings multiples represent what one share can buy for an equity investor. As of September 27, Bristol-Myers Squibb (BMY) was trading at a forward PE multiple of ~19.9x, compared to the industry average of 15.9x. Competitors Eli Lilly and Co. (LLY), Merck & Co. (MRK), and Pfizer (PFE) are trading at forward PEs of 18.6x, 15.8x, and 13.1x, respectively.

Forward EV/EBITDA

On a capital structure–neutral and excess cash-adjusted basis, Bristol-Myers Squibb currently trades at ~16.7x, which is much higher than the industry’s average of ~11.9x. Other competitors Eli Lilly and Co. (LLY), Merck & Co. (MRK), and Pfizer (PFE) have forward EV/EBITDA multiples of 13.8x, 11.8x, and 10.7x, respectively.

Analyst recommendations

As per data on September 27, Bristol-Myers’s stock value has risen 13.4% over the last 12 months. Analysts estimate that the stock price will fall 7.4% over the next 12 months. Wall Street analysts’ recommendations show a 12-month targeted price of $58.27 per share compared to the last price of $62.93 per share as of August 26. Also, out of 23 analysts covering Bristol-Myers Squibb, nine recommend a “buy,” 11 recommend a “hold,” and three recommend a “sell.” The consensus rating for Bristol-Myers Squibb is 2.48, which represents a moderate buy for value investors.

To divest company-specific risks, investors can consider ETFs like the Health Care Select Sector SPDR ETF (XLV), which invests 3.2% of its total assets in Bristol-Myers Squibb (BMY). XLV also invests 2.5% in Eli Lilly and Co. (LLY), 5.6% in Merck and Co. (MRK), and 6.4% in Pfizer (PFE).

X

Please select a profession that best describes you: